Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA ingrown toenail drug "feedback" meeting

This article was originally published in The Tan Sheet

Executive Summary

FDA ingrown toenail drug "feedback" meeting: With Schering- Plough about addition of sodium sulfide 1% to the ingrown toenail relief OTC drug monograph will be held Jan. 20 at the request of Schering-Plough, which markets Dr. Scholl's foot care products. The company petitioned the agency for the monograph amendment in May 1994; FDA has raised concerns about the ingredient's safety. Schering-Plough Scientific and Regulatory Affairs Senior VP John Clayton, PhD, and Clinical Research/Regulatory Affairs VP Ronald Garutti, MD, will attend. The meeting will take place at 9201 Corporate Blvd., S200, Rockville, Md., starting at 9:30 a.m. For more information on the meeting, contact FDA's Melvin Lessing at (301) 827-2271...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel